A research paper by joint research with Nanjing Medical University has been published in an international academic journal

The results of a joint research project between SOCIUM Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Katsuhisa Horimoto) and the School of Pharmacy of Nanjing Medical University have been published in the journal, Cell Death & Differentiation [IF 13.7], on June 18 (https://doi.org/10.1038/s41418-025-01534-3).

This study was led by Professor Han Feng, Professor and Dean of the School of Pharmacy of Nanjing Medical University, and the paper reports on the discovery of a new target molecule in glioblastoma (#1), a type of brain tumor and the most malignant form of glioma (https://mp.weixin.qq.com/s/bu-VLc4Fy7Ngbj4mnJom0g).Our company accelerates the discovery and development of target molecules and drug candidates for various diseases through our proprietary AI platform and robust cross-border collaborations with research institutions such as Nanjing Medical University.

【About SOCIUM Inc.】
SOCIUM Inc. is a venture company that uses AI platform technology to discover drug discovery seeds, especially drug candidates for rare diseases. With the vision of “medicine for those without medicine, medicine for those who cannot afford medicine”, we are working to overcome the unmet medical needs of patients. For more information on our unique approach to drug discovery, please refer to the relevant section of our website (https://socium.co.jp/drug_discovery/).

#1 The most aggressive and most common type of cancer that originates in the brain, with a very poor prognosis for survival. (https://en.wikipedia.org/wiki/Glioblastoma)

For inquiries regarding this matter, please contact
SOCIUM Inc.
5th, 6th, and 7th floors of Waterfront Center Annex, National Institute of Advanced Industrial Science and Technology (AIST)
2-4-7 Aomi, Koto-ku, Tokyo, Japan 1350064
https://socium.co.jp
E-mail: contact@socium.co.jp